| Oryzon

Skip to main content

English
Español

Company
- Overview
- Strategy
- Team
Epigenetics
- Epigenetics
- LSD1
Programs
Patients
- Clinical Trials
Investors
News & Events
- Press releases
- Events
Contact

Search

Breadcrumb

Home

5 January 2016

Oryzon to Attend the 34th Annual J.P. Morgan Healthcare Conference in San Francisco

6-9 December 2025

67th American Society of Hematology (ASH) Annual Meeting

Orlando

FL

United States

Read more about Junta accionistas 2025 - Noviembre - EN

12 December 2025

Extraordinary General Shareholders’ Meeting 2025 December

7 November 2025

ORYZON reports financial results and corporate update for quarter ended September 30, 2025

4 November 2025

ORYZON announces positive clinical data of iadademstat at ASH-2025

3 November 2025

ORYZON announces First‑Patient‑In (FPI) in RESTORE Phase Ib trial of iadademstat in sickle cell disease

17-20 November 2025

Jefferies Global Healthcare Conference

Waldorf Hilton

London

United Kingdom

17 November 2025

LSX Investival Showcase Europe 2025

Old Billingsgate

London

United Kingdom

3-5 November 2025

BIO-EUROPE

Viena Congress and Convention Center

Viena

Austria

Pagination

First page «
Previous page ‹
Current page 1
Page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
Next page ›
Last page »

Subscribe to

Company

Overview
Strategy
Team

Epigenetics

Epigenetics
LSD1

Programs

Pipeline
Iadademstat
Vafidemstat
Collaborations
Publications

Patients

Clinical Trials

Investors

Share Information
Financial Information
CNMV Filings
Analyst Coverage
Corporate Governance
Corporate Social Responsibility

News & Events

Press releases
Events

Contact

Contact
Email Alerts
Join us

© Oryzon Genomics, S.A. - All Rights Reserved

Legal
Privacy Policy
Cookie Policy
Ethics Channel